Sign-up for our monthly newsletter!

Sign-up for the M&A Perspective Newsletter!

Sign-up for the Arbitration Case Alert Newsletter!

 
News

Santhera Enters into Option and Sublicense Agreement with Idorsia

22.11.2018 – Santhera Pharmaceuticals (SIX: SANN) is a Swiss specialty pharmaceutical company focused on the development and commercialization of innovative medicines for rare and other diseases with high unmet medical needs. On 20 November 2018, Santhera Pharmaceuticals announced that it had entered into an agreement with Idorsia Ltd (SIX: IDIA) under which Santhera will acquire the option to exclusively in-license, by way of sublicense, the steroid vamorolone in all indications and all countries worldwide except Japan and South Korea. Vamorolone is a highly promising drug candidate for the treatment of patients with Duchenne muscular dystrophy.

Schellenberg Wittmer advised Santhera Pharmaceuticals on this matter.

The team was led by Philipp Groz (IP / Life Sciences) and included Marcel Jakob (Corporate/M&A).